Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000341

Drug Information
NameMibefradil
SynonymsCHEBI:172035; AC1L1TOE; CID60663; DB01388; (1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate; C29H38FN3O3; CHEMBL45816; C07222; 2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1S-cis)-; BRD-K09549677-300-01-8; Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-; AC1Q4NDV; [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate; NCGC00161420-01; NCGC00161420-03; Lopac-M-5441; Mibefradil; (1S-cis)-2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate; NCGC00015683-01; 116644-53-2; 116666-63-8 (dihydrochloride); Mibefradil (INN); Lopac0_000748; LS-172325; NCGC00161420-04; Mibefradil [INN:BAN]; (1s,2s)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate; D08217
CompanyRoche
IndicationHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Withdrawal    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-
27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-
6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0
/s1
InChIKeyHBNPJJILLOYFJU-VMPREFPWSA-N
Canonical SMILESCC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F    
Isomeric SMILESCC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
CAS NumberCAS 116644-53-2
FormulaC29H38FN3O3
PubChem Compound IDCID 60663.
PubChem Substance IDSID 9431.
SuperDrug ATC IDC08CX01
SuperDrug CAS ID116644532;
TargetVoltage-dependent T-type calcium channelBlocker[1][2][3][4]
Ref 1T-type calcium channel blockade in the management of chronic ischemic heart disease. Cardiovasc Drugs Ther. 2000 Oct;14(5):459-61. To Reference
Ref 2Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol. 2000 Jan-Feb;14(1):31-41. To Reference
Ref 3Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels. Neuropharmacology. 2000;39(1):1-10. To Reference
Ref 4Voltage-gated T-type Ca2+ channels and heart failure. Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):429-37. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543